KalVista raises $60M in public offering and private placement to fund sebetralstat

KalVista Pharmaceuticals, Inc.

Public offering of 5.5M shares at $10.00 per share for gross proceeds of $55M; net ~$51.3M.
Concurrent private placement of 500K shares to DRI Healthcare Acquisitions LP for $5M gross; net ~$4.7M.
Proceeds will fund continued clinical development of sebetralstat and pre-commercialization activities.
Offering and private placement expected to close November 5, 2024; closings not contingent on each other.
Jefferies, BofA Securities, TD Cowen, and Stifel serving as joint book-running managers and placement agents.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.